GlassScriptPhysician profile
Marguerite B Picou
NPI 1033115159
$3,439.15
in general payments reported to CMS, 2019-2025
33 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $571 · 2021: $842 · 2022: $201 · 2023: $373 · 2024: $681 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reapplix INC. | $530.42 | 2023-2024 | 3c Patch Kit - Box |
| Kerecis Limited | $443.03 | 2021-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Lilly USA, LLC | $247.84 | 2019-2023 | Jardiance |
| Pfizer INC. | $221.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $219.42 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $178.19 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.81 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $148.42 | 2021-2025 | Nuzyra, Xhance |
| Novo Nordisk INC | $141.93 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $140.34 | 2019-2022 | |
| Astellas Pharma US INC | $137.57 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $78.39 | 2019-2021 | |
| Esperion Therapeutics, INC. | $68.04 | 2021 | |
| Allergan, INC. | $66.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $66.66 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $60.18 | 2019-2025 | Collagenase Santyl |
| Novartis Pharmaceuticals Corporation | $53.39 | 2019-2021 | |
| Acera Surgical, INC. | $49.45 | 2024 | Restrata Wound Matrix |
| Takeda Pharmaceuticals U.S.A., INC. | $46.60 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.41 | 2020-2023 | Xifaxan |
| Convatec INC. | $46.38 | 2022-2025 | |
| Amgen INC. | $44.91 | 2019-2024 | Prolia, Evenity |
| Abbvie INC. | $29.84 | 2021-2025 | |
| Tei Medical INC. | $29.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.22 | 2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $17.09 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $16.05 | 2023 | |
| Mylan Specialty L.P. | $15.19 | 2021 | |
| Acadia Pharmaceuticals INC | $14.47 | 2019 | |
| Shield Therapeutics INC | $14.11 | 2024 | |
| Exact Sciences Corporation | $12.95 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marguerite Picou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.